FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Brian Houston

Research Profile

Anatomy

Chemicals & Drugs

Living Beings

Phenomena

Metabolic Clearance Rate

Concepts & Ideas

Physiology

Co-author Network

Publications

TOP 3
Katherine L Gill; J Brian Houston; Michael Gertz; Aleksandra Galetin
Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data.
Michael Gertz; Michael J Hobbs; J Brian Houston; KE Kenworthy; Malcolm Rowland; Catherine M Cartwright; Aleksandra Galetin
Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.
J Brian Houston; Karen Rowland Yeo; Ugo Zanelli
Evaluation of the novel in vitro systems for hepatic drug clearance and assessment of their predictive utility.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Brian Houston (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Katherine L Gill; J Brian Houston; Michael Gertz; Aleksandra Galetin
Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data.
Drug metabolism and disposition: the biological fate of chemicals 2013;41(4):744-53.
2013: Michael Gertz; Michael J Hobbs; J Brian Houston; KE Kenworthy; Malcolm Rowland; Catherine M Cartwright; Aleksandra Galetin
Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.
Pharmaceutical research 2013;30(3):761-80.
2012: J Brian Houston; Karen Rowland Yeo; Ugo Zanelli
Evaluation of the novel in vitro systems for hepatic drug clearance and assessment of their predictive utility.
Toxicology in vitro : an international journal published in association with BIBRA 2012;26(8):1265-71.
2012: Karelle Ménochet; J Brian Houston; KE Kenworthy; Aleksandra Galetin
Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(9):1744-56.
2012: Howard J Burt; Claire Collins; J Brian Houston; Ruth Hyland; Henry Pertinez; Carolina Säll; Aleksandra Galetin
Progress curve mechanistic modeling approach for assessing time-dependent inhibition of CYP3A4.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(9):1658-67.
2012: David Hallifax; J Brian Houston
Evaluation of hepatic clearance prediction using in vitro data: emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs.
Journal of pharmaceutical sciences 2012;101(8):2645-52.
2012: Emilie Jigorel; J Brian Houston
Utility of drug depletion-time profiles in isolated hepatocytes for accessing hepatic uptake clearance: identifying rate-limiting steps and role of passive processes.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(8):1596-602.
2012: Carolina Säll; J Brian Houston; Aleksandra Galetin
A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(7):1279-89.
2012: David Hallifax; Elisa Turlizzi; Ugo Zanelli; J Brian Houston
Clearance-dependent underprediction of in vivo intrinsic clearance from human hepatocytes: comparison with permeabilities from artificial membrane (PAMPA) assay, in silico and caco-2 assay, for 65 drugs.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2012;45(5):570-4.
2012: Katherine L Gill; J Brian Houston; Aleksandra Galetin
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(4):825-35.
2012: Karelle Ménochet; J Brian Houston; KE Kenworthy; Aleksandra Galetin
Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model.
The Journal of pharmacology and experimental therapeutics 2012;341(1):2-15.
2011: Ian E Templeton; J Brian Houston; Aleksandra Galetin
Predictive utility of in vitro rifampin induction data generated in fresh and cryopreserved human hepatocytes, Fa2N-4, and HepaRG cells.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(10):1921-9.
2011: Yoshiyuki Yabe; Aleksandra Galetin; J Brian Houston
Kinetic characterization of rat hepatic uptake of 16 actively transported drugs.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(10):1808-14.
2011: Michael Gertz; J Brian Houston; Aleksandra Galetin
Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(9):1633-42.
2011: Helen E Cubitt; J Brian Houston; Aleksandra Galetin
Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(5):864-73.
2011: Joanne A Foster; J Brian Houston; David Hallifax
Comparison of intrinsic clearances in human liver microsomes and suspended hepatocytes from the same donor livers: clearance-dependent relationship and implications for prediction of in vivo clearance.
Xenobiotica; the fate of foreign compounds in biological systems 2011;41(2):124-36.
2011: Eleanor J Guest; Leon Aarons; J Brian Houston; Amin Rostami-Hodjegan; Aleksandra Galetin
Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(2):170-3.
2011: Eleanor J Guest; Karen Rowland Yeo; Amin Rostami-Hodjegan; Geoffrey T Tucker; J Brian Houston; Aleksandra Galetin
Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.
British journal of clinical pharmacology 2011;71(1):72-87.
2010: Hayley S Brown; Alison J Wilby; Jane Alder; J Brian Houston
Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay.
Drug metabolism and disposition: the biological fate of chemicals 2010;38(12):2139-46.
2010: David Hallifax; Joanne A Foster; J Brian Houston
Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view.
Pharmaceutical research 2010;27(10):2150-61.
2010: M Teresa Donato; David Hallifax; Laura Picazo; José V Castell; J Brian Houston; M José Gomez-Lechón; Agustin Lahoz
Metabolite formation kinetics and intrinsic clearance of phenacetin, tolbutamide, alprazolam, and midazolam in adenoviral cytochrome P450-transfected HepG2 cells and comparison with hepatocytes and in vivo.
Drug metabolism and disposition: the biological fate of chemicals 2010;38(9):1449-55.
2010: Michael Gertz; Anthony Harrison; J Brian Houston; Aleksandra Galetin
Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data.
Drug metabolism and disposition: the biological fate of chemicals 2010;38(7):1147-58.
2010: Howard J Burt; Aleksandra Galetin; J Brian Houston
IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4.
Xenobiotica; the fate of foreign compounds in biological systems 2010;40(5):331-43.
2010: Aleksandra Galetin; Michael Gertz; J Brian Houston
Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions.
Drug metabolism and pharmacokinetics 2010;25(1):28-47.
2009: Raj Badhan; Jeffrey Penny; Aleksandra Galetin; J Brian Houston
Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption.
Journal of pharmaceutical sciences 2009;98(6):2180-97.
2009: Helen E Cubitt; J Brian Houston; Aleksandra Galetin
Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.
Pharmaceutical research 2009;26(5):1073-83.
2009: David Hallifax; J Brian Houston
Methodological uncertainty in quantitative prediction of human hepatic clearance from in vitro experimental systems.
Current drug metabolism 2009;10(3):307-21.
2008: J Brian Houston; Aleksandra Galetin
Methods for predicting in vivo pharmacokinetics using data from in vitro assays.
Current drug metabolism 2008;9(9):940-51.
2008: Michael Gertz; John D Davis; Anthony Harrison; J Brian Houston; Aleksandra Galetin
Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations.
Current drug metabolism 2008;9(8):785-95.
2008: Verawan Uchaipichat; Aleksandra Galetin; J Brian Houston; Peter I Mackenzie; J Andrew Williams; John O Miners
Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites.
Molecular pharmacology 2008;74(4):1152-62.
2008: Aleksandra Galetin; Michael Gertz; J Brian Houston
Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions.
Expert opinion on drug metabolism & toxicology 2008;4(7):909-22.
2008: Alison J Parker; J Brian Houston
Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(7):1375-84.
2008: Jamie Henshall; Aleksandra Galetin; Anthony Harrison; J Brian Houston
Comparative analysis of CYP3A heteroactivation by steroid hormones and flavonoids in different in vitro systems and potential in vivo implications.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(7):1332-40.
2008: Peter J Kilford; Michael Gertz; J Brian Houston; Aleksandra Galetin
Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(7):1194-7.
2008: Laura K Hinton; Aleksandra Galetin; J Brian Houston
Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions.
Pharmaceutical research 2008;25(5):1063-74.
2008: David Hallifax; Aleksandra Galetin; J Brian Houston
Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines.
Xenobiotica; the fate of foreign compounds in biological systems 2008;38(4):353-67.
2008: Michael Gertz; Peter J Kilford; J Brian Houston; Aleksandra Galetin
Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(3):535-42.
2007: Hayley S Brown; Anthony Chadwick; J Brian Houston
Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(11):2119-26.
2007: Aleksandra Galetin; Laura K Hinton; Howard Burt; R Scott Obach; J Brian Houston
Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.
Current drug metabolism 2007;8(7):685-93.
2007: GI Somers; MK Bayliss; J Brian Houston
The metabolism of the 5HT3 antagonists, ondansetron, alosetron and GR87442 II: investigation into the in vitro methods used to predict the in vivo hepatic clearance of ondansetron, alosetron and GR87442 in the rat, dog and human.
Xenobiotica; the fate of foreign compounds in biological systems 2007;37(8):855-69.
2007: GI Somers; A J Harris; MK Bayliss; J Brian Houston
The metabolism of the 5HT3 antagonists ondansetron, alosetron and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes.
Xenobiotica; the fate of foreign compounds in biological systems 2007;37(8):832-54.
2007: David Hallifax; J Brian Houston
Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(8):1325-32.
2007: Hayley S Brown; Michael Griffin; J Brian Houston
Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(2):293-301.
2007: Nicola J Hewitt; María José Gómez Lechón; J Brian Houston; David Hallifax; Hayley S Brown; Patrick Maurel; J Gerald Kenna; Lena Gustavsson; Christina Lohmann; Christian Skonberg; André Guillouzo; Gregor Tuschl; Albert P Li; Edward LeCluyse; Geny M M Groothuis; Jan G Hengstler
Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies.
Drug metabolism reviews 2007;39(1):159-234.
2007: Zoe E Barter; Martin K Bayliss; Philip H Beaune; Alan R Boobis; David J Carlile; Robert J Edwards; J Brian Houston; Brian G Lake; John C Lipscomb; Olavi Pelkonen; Geoffrey T Tucker; Amin Rostami-Hodjegan
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.
Current drug metabolism 2007;8(1):33-45.
2006: David Hallifax; J Brian Houston
Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(11):1829-36.
2006: Aleksandra Galetin; J Brian Houston
Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism.
The Journal of pharmacology and experimental therapeutics 2006;318(3):1220-9.
2006: John O Miners; Kathleen M Knights; J Brian Houston; Peter I Mackenzie
In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises.
Biochemical pharmacology 2006;71(11):1531-9.
2006: David Hallifax; J Brian Houston
Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(4):724-6; author reply 727.
2006: Nancy Hakooz; Kiyomi Ito; Helen C Rawden; Helen Gill; Lynn Lemmers; Alan R Boobis; Robert J Edwards; David J Carlile; Brian G Lake; J Brian Houston
Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance.
Pharmaceutical research 2006;23(3):533-9.
2006: Hayley S Brown; Aleksandra Galetin; David Hallifax; J Brian Houston
Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Clinical pharmacokinetics 2006;45(10):1035-50.
2006: Aleksandra Galetin; Howard Burt; Laura Gibbons; J Brian Houston
Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(1):166-75.
2005: David Hallifax; Helen C Rawden; Nancy Hakooz; J Brian Houston
Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(12):1852-8.
2005: Hayley S Brown; Kiyomi Ito; Aleksandra Galetin; J Brian Houston
Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.
British journal of clinical pharmacology 2005;60(5):508-18.
2005: Aleksandra Galetin; Kiyomi Ito; David Hallifax; J Brian Houston
CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.
The Journal of pharmacology and experimental therapeutics 2005;314(1):180-90.
2005: Helen C Rawden; David J Carlile; A Tindall; David Hallifax; Aleksandra Galetin; Kiyomi Ito; J Brian Houston
Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans.
Xenobiotica; the fate of foreign compounds in biological systems 2005;35(6):603-25.
2005: Kiyomi Ito; David Hallifax; R Scott Obach; J Brian Houston
Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(6):837-44.
2005: Hannah M Jones; G Nicholls; J Brian Houston
Impact of end-product inhibition on the determination of in vitro metabolic clearance.
Xenobiotica; the fate of foreign compounds in biological systems 2005;35(5):439-54.
2005: J Brian Houston; Aleksandra Galetin
Modelling atypical CYP3A4 kinetics: principles and pragmatism.
Archives of biochemistry and biophysics 2005;433(2):351-60.
2005: Kiyomi Ito; J Brian Houston
Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches.
Pharmaceutical research 2005;22(1):103-12.
2005: Sarah J Griffin; J Brian Houston
Prediction of in vitro intrinsic clearance from hepatocytes: comparison of suspensions and monolayer cultures.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(1):115-20.
2004: Aleksandra Galetin; Caroline Brown; David Hallifax; Kiyomi Ito; J Brian Houston
Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(12):1411-20.
2004: Hannah M Jones; J Brian Houston
Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(9):973-82.
2004: Kiyomi Ito; J Brian Houston
Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.
Pharmaceutical research 2004;21(5):785-92.
2004: Hannah M Jones; David Hallifax; J Brian Houston
Quantitative prediction of the in vivo inhibition of diazepam metabolism by omeprazole using rat liver microsomes and hepatocytes.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(5):572-80.
2004: Sarah J Griffin; J Brian Houston
Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(5):552-8.
2004: Verawan Uchaipichat; Peter I Mackenzie; Xiao-Hui Guo; Dione A Gardner-Stephen; Aleksandra Galetin; J Brian Houston; John O Miners
Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid.
Drug metabolism and disposition: the biological fate of chemicals 2004;32(4):413-23.
2004: Kiyomi Ito; Hayley S Brown; J Brian Houston
Database analyses for the prediction of in vivo drug-drug interactions from in vitro data.
British journal of clinical pharmacology 2004;57(4):473-86.
2003: J Brian Houston; Aleksandra Galetin
Progress towards prediction of human pharmacokinetic parameters from in vitro technologies.
Drug metabolism reviews 2003;35(4):393-415.
2003: Aleksandra Galetin; Stephen E Clarke; J Brian Houston
Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(9):1108-16.
2003: Andrew N Stone; Peter I Mackenzie; Aleksandra Galetin; J Brian Houston; John O Miners
Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7.
Drug metabolism and disposition: the biological fate of chemicals 2003;31(9):1086-9.
2002: Aleksandra Galetin; Stephen E Clarke; J Brian Houston
Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(12):1512-22.
2002: J Andrews; M F Abd-Ellah; N L Randolph; KE Kenworthy; David J Carlile; T Friedberg; J Brian Houston
Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells.
Xenobiotica; the fate of foreign compounds in biological systems 2002;32(11):937-47.
2001: KE Kenworthy; Stephen E Clarke; J Andrews; J Brian Houston
Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(12):1644-51.
2000: J Brian Houston; KE Kenworthy
In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(3):246-54.
1999: KE Kenworthy; JC Bloomer; Stephen E Clarke; J Brian Houston
CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.
British journal of clinical pharmacology 1999;48(5):716-27.
1999: L E Witherow; J Brian Houston
Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat.
The Journal of pharmacology and experimental therapeutics 1999;290(1):58-65.
1999: David J Carlile; Nancy Hakooz; M K Bayliss; J Brian Houston
Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.
British journal of clinical pharmacology 1999;47(6):625-35.
1999: David J Carlile; Nancy Hakooz; J Brian Houston
Kinetics of drug metabolism in rat liver slices: IV. Comparison of ethoxycoumarin clearance by liver slices, isolated hepatocytes, and hepatic microsomes from rats pretreated with known modifiers of cytochrome P-450 activity.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(4):526-32.
1998: David J Carlile; A J Stevens; E I Ashforth; D Waghela; J Brian Houston
In vivo clearance of ethoxycoumarin and its prediction from In vitro systems. Use Of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes.
Drug metabolism and disposition: the biological fate of chemicals 1998;26(3):216-21.
1997: J Brian Houston; David J Carlile
Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices.
Drug metabolism reviews 1997;29(4):891-922.
1997: J Brian Houston; David J Carlile
Incorporation of in vitro drug metabolism data into physiologically-based pharmacokinetic models.
Toxicology in vitro : an international journal published in association with BIBRA 1997;11(5):473-8.
1997: David J Carlile; K Zomorodi; J Brian Houston
Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam.
Drug metabolism and disposition: the biological fate of chemicals 1997;25(8):903-11.
1997: P D Worboys; A Bradbury; J Brian Houston
Kinetics of drug metabolism in rat liver slices. III. Relationship between metabolic clearance and slice uptake rate.
Drug metabolism and disposition: the biological fate of chemicals 1997;25(4):460-7.
1997: K Zomorodi; J Brian Houston
Selectivity of omeprazole inhibition towards rat liver cytochromes P450.
Xenobiotica; the fate of foreign compounds in biological systems 1997;27(1):49-58.
1996: P D Worboys; B Brennan; A Bradbury; J Brian Houston
Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition.
Xenobiotica; the fate of foreign compounds in biological systems 1996;26(9):897-907.
1996: K Zomorodi; J Brian Houston
Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes.
British journal of clinical pharmacology 1996;42(2):157-62.
1996: P D Worboys; A Bradbury; J Brian Houston
Kinetics of drug metabolism in rat liver slices. II. Comparison of clearance by liver slices and freshly isolated hepatocytes.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(6):676-81.
1996: C M Ervine; D E Matthew; B Brennan; J Brian Houston
Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(2):211-5.
1995: A J Stevens; S W Martin; B S Brennan; A McLachlan; L A Gifford; M Rowland; J Brian Houston
Regional drug delivery II: relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation.
Pharmaceutical research 1995;12(12):1987-96.
1995: S W Martin; A J Stevens; B S Brennan; M L Reis; L A Gifford; M Rowland; J Brian Houston
Regional drug delivery I: permeability characteristics of the rat 6-day-old air pouch model of inflammation.
Pharmaceutical research 1995;12(12):1980-6.
1995: K Zomorodi; J Brian Houston
Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies.
Pharmaceutical research 1995;12(11):1642-6.
1995: K Zomorodi; David J Carlile; J Brian Houston
Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance.
Xenobiotica; the fate of foreign compounds in biological systems 1995;25(9):907-16.
1995: J Ford; S W Martin; J Brian Houston
Assessment of intestinal permeability changes induced by nonsteroidal anti-inflammatory drugs in the rat.
Journal of pharmacological and toxicological methods 1995;34(1):9-16.
1995: E I Ashforth; David J Carlile; R Chenery; J Brian Houston
Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.
The Journal of pharmacology and experimental therapeutics 1995;274(2):761-6.
1995: J Ford; J Brian Houston
Concentration-response relationships for three nonsteroidal anti-inflammatory drugs in the rat intestine.
Human & experimental toxicology 1995;14(7):573-9.
1995: S W Martin; A J Stevens; B S Brennan; M Rowland; J Brian Houston
Pharmacodynamic comparison of regional drug delivery for non-steroidal anti-inflammatory drugs, using the rat air-pouch model of inflammation.
The Journal of pharmacy and pharmacology 1995;47(6):458-61.
1995: J D Davis; Leon Aarons; J Brian Houston
Metabolism of theophylline and its inhibition by fluoroquinolones in rat hepatic microsomes.
Xenobiotica; the fate of foreign compounds in biological systems 1995;25(6):563-73.
1995: P D Worboys; A Bradbury; J Brian Houston
Kinetics of drug metabolism in rat liver slices. Rates of oxidation of ethoxycoumarin and tolbutamide, examples of high- and low-clearance compounds.
Drug metabolism and disposition: the biological fate of chemicals 1995;23(3):393-7.
1995: K A Hayes; B Brennan; R Chenery; J Brian Houston
In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data.
Drug metabolism and disposition: the biological fate of chemicals 1995;23(3):349-53.
1994: S W Martin; A J Stevens; B S Brennan; D Davies; M Rowland; J Brian Houston
The six-day-old rat air pouch model of inflammation: characterization of the inflammatory response to carrageenan.
Journal of pharmacological and toxicological methods 1994;32(3):139-47.
1994: J D Davis; Leon Aarons; J Brian Houston
Relationship between enoxacin and ciprofloxacin plasma concentrations and theophylline disposition.
Pharmaceutical research 1994;11(10):1424-8.
1994: J Brian Houston
Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics.
Toxicology in vitro : an international journal published in association with BIBRA 1994;8(4):507-12.
1994: C M Ervine; J Brian Houston
Disposition of azole antifungal agents. III. Binding of fluconazole and other azoles in rat liver.
Pharmaceutical research 1994;11(7):961-5.
1994: H L Bomont; M H Tarbit; M J Humphrey; J Brian Houston
Disposition of azole antifungal agents. II. Hepatic binding and clearance of dichlorophenyl-bis-triazolylpropanol (DTP) in the rat.
Pharmaceutical research 1994;11(7):951-60.
1994: J Brian Houston
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.
Biochemical pharmacology 1994;47(9):1469-79.
1994: A J Stevens; S W Martin; B S Brennan; M Rowland; J Brian Houston
Experimental determination of a drug targeting index for S(+)ibuprofen using the rat air pouch model of inflammation.
Journal of drug targeting 1994;2(4):333-9.
1993: J D Davis; Leon Aarons; J Brian Houston
Simultaneous assay of fluoroquinolones and theophylline in plasma by high-performance liquid chromatography.
Journal of chromatography 1993;621(1):105-9.
1993: D Matthew; B Brennan; K Zomorodi; J Brian Houston
Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver.
Pharmaceutical research 1993;10(3):418-22.
1993: A Adedoyin; Leon Aarons; J Brian Houston
Time-dependent disposition of beta-naphthoflavone in the rat.
Pharmaceutical research 1993;10(1):35-43.
1992: D E Davies; A J Stevens; J Brian Houston
Use of the rat air pouch model of inflammation to evaluate regional drug delivery.
Agents and actions 1992;Spec No():C109-11.
1990: D E Matthew; J Brian Houston
Drug metabolizing capacity in vitro and in vivo--II. Correlations between hepatic microsomal monooxygenase markers in phenobarbital-induced rats.
Biochemical pharmacology 1990;40(4):751-8.
1990: D E Matthew; J Brian Houston
Drug metabolizing capacity in vitro and in vivo--I. Correlations between hepatic microsomal monooxygenase markers in beta-naphthoflavone-induced rats.
Biochemical pharmacology 1990;40(4):743-9.
1988: J Brian Houston; M J Humphrey; D E Matthew; M H Tarbit
Comparison of two azole antifungal drugs, ketoconazole, and fluconazole, as modifiers of rat hepatic monooxygenase activity.
Biochemical pharmacology 1988;37(3):401-8.
1987: M Mistry; J Brian Houston
Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine.
Drug metabolism and disposition: the biological fate of chemicals 1987;15(5):710-7.
1987: A Adedoyin; Leon Aarons; J Brian Houston
Dose-dependent pharmacokinetics of cimetidine in the rat.
Xenobiotica; the fate of foreign compounds in biological systems 1987;17(5):595-604.
1987: A Adedoyin; Leon Aarons; J Brian Houston
High-performance liquid chromatographic determination of beta-naphthoflavone in biological fluids.
Journal of chromatography 1987;416(1):160-4.
1987: A Adedoyin; Leon Aarons; J Brian Houston
Plasma concentration-response relationship for cimetidine inhibition of drug metabolism in the rat.
Drug metabolism and disposition: the biological fate of chemicals 1987;15(1):127-32.
1986: P N Shaw; J Tseti; S Warburton; A Adedoyin; J Brian Houston
Inhibition of antipyrine metabolite formation. Steady state studies with cimetidine and metyrapone in rats.
Drug metabolism and disposition: the biological fate of chemicals 1986;14(2):271-6.
1985: A Adedoyin; Leon Aarons; J Brian Houston
High-performance liquid chromatographic method for the simultaneous determination of cimetidine and antipyrine in plasma.
Journal of chromatography 1985;345(1):192-6.